Page 65 - Read Online

Page 14 of 17 Gulati et al. Metab Target Organ Damage 2024;4:9 https://dx.doi.org/10.20517/mtod.2023.45

DECLARATIONS
Authors’ Contributions
Conducted literature review and writing of the manuscript: Gulati R
Contributed to the conception of the review and editing of the manuscript: Wegermann K
Contributed to the editing of the manuscript: Moylan CA, Wilder J

Availability of Data and Materials
Not applicable.

Financial Support and Sponsorship
None.

Conflicts of Interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for Publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new
fatty liver disease nomenclature. Hepatology 2023;78:1966-86. DOI PubMed PMC
2. Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty
liver disease. Medicines 2019;6:41. DOI PubMed PMC
3. Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol 2023;21:1978-91. DOI
PubMed
4. Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin
Transl Hepatol 2020;8:76-86. DOI PubMed PMC
5. Li W, Ng CH, Quek J, et al. The growing prevalence of nonalcoholic fatty liver disease (NAFLD), determined by fatty liver index,
amongst young adults in the United States. A 20-year experience. Metab Target Organ Damage 2022;2:19. DOI
6. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an
exponential increase in burden of disease. Hepatology 2018;67:123-33. DOI PubMed PMC
7. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore
identical. J Hepatol 2024;80:e76-7. DOI PubMed
8. Nasr P, Jönsson C, Ekstedt M, Kechagias S. Non-metabolic causes of steatotic liver disease. Metab Target Organ Damage 2023;3:19.
DOI
9. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol
2024;80:e54-6. DOI PubMed
10. Patel P, Muller C, Paul S. Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-
analysis. World J Hepatol 2020;12:506-18. DOI PubMed PMC
11. Jennings J, Faselis C, Yao MD. NAFLD-NASH: An under-recognized epidemic. Curr Vasc Pharmacol 2018;16:209-13. DOI
PubMed
12. Thandra KC, Barsouk A, Saginala K, Aluru JS, Rawla P, Barsouk A. Epidemiology of non-alcoholic fatty liver disease and risk of
hepatocellular carcinoma progression. Clin Exp Hepatol 2020;6:289-94. DOI PubMed PMC
13. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of
ethnicity. Hepatology 2004;40:1387-95. DOI
14. Rich NE, Oji S, Mufti AR, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in
the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:198-210.e2. DOI PubMed PMC
15. Talens M, Tumas N, Lazarus JV, Benach J, Pericàs JM. What do we know about inequalities in NAFLD distribution and outcomes? A